Objectives-To evaluate whether diastolic dysfunction derived by tissue Doppler imaging (TDI) would be an earlier manifestation in genotype-positive hypertrophic cardiomyopathy (HCM) subjects without left ventricular hypertrophy (LVH).
H ypertrophic cardiomyopathy (HCM) is caused primarily by hundreds of dominant mutations on 13 genes encoding sarcomere proteins with inherited tendency. 1, 2 Family members of HCM-overt patients carrying disease-causing mutations without left ventricular hypertrophy (LVH) are usually referred to as "genotype-positive/left ventricular hypertrophy-negative" (G1/ LVH2) subjects. 3, 4 According to the published cases or evidence, this G1/LVH2 group of people are at risk of developing typical HCM, arrhythmia, heart failure, or even sudden death. [5] [6] [7] [8] Taking these risks into consideration, G1/LVH2 subjects are supposed to take complete cardiac exam and lifelong follow-up for genetic counseling, risk stratification, lifestyle guidance, and therapy.
The HCM G1/LVH2 subjects are characterized by myocardial functional or histopathological abnormalities. [9] [10] [11] These group of people may have altered manifestation in several aspects such as gene screening, electrocardiogram, echocardiogram, cardiac magnetic resonance, and endomyocardial biopsy. 12 Among all of these methods, the tissue Doppler imaging (TDI) technique of echocardiography makes it possible for myocardial velocity measurement and further load-independent diastolic function assessment. Moreover, TDI has the advantages of being reproducible, noninvasive, and economical. Several animal experiments have demonstrated that diastolic function derived by TDI decreased in the G1/LVH2 group. [13] [14] [15] As for human being studies, the result was unstable. According to the the research by Ho in 2002 and Mohamed in 2014, TDI measurements Ea on septum and lateral wall both decreased in the G1/LVH2 subjects. Plus, Mohamed F. A's study also showed increased E/Ea value compared with healthy controls. The TDI appeared to be valuable for detecting G1/LVH2 subjects' diastolic dysfunction in some studies, 16, 17 whereas it was questioned in others. 18, 19 Silva carried out an experiment on 34 first-degree relatives of overt HCM Caucasians, only to find that there was no significant difference derived by TDI between the G1/LVH2 and control groups. Given the controversial statements, we performed a meta-analysis to expect a convincible result about the alteration of TDIderived diastolic function of HCM gene mutation carriers with normal wall thickness.
Materials and Methods

Publication Search
We searched Pubmed, Medline, and Web of Science with an upper date limit of June 30, 2016 . The following terms related to HCM G1/LVH2 subjects and their diastolic function assessed by TDI were included: "hypertrophic cardiomyopathy" or "HCM"; "preclinical" or "subclinical"; "carrier" or "genotype-positive"; "echocardiography"; "diastolic function"; and "tissue Doppler imaging" or "TDI." In addition, we also looked through the references of the articles for any possible information.
Inclusion Criteria (1) The primary studies have to be case-control design containing at least two groups: G1/LVH-group (or preclinical HCM group) and control group. (2) None of the subjects in G1/LVH-group has been treated. It is necessary to refer to the disagreements to the third author (J.Y.) when the eligibility of studies is questioned.
Data Extraction
We designed a table that includes all of the information. The following data were extracted by two of the authors (Table S1 ); and (2) results of TDI measurements for diastolic function: early diastolic annular velocity (Ea), late diastolic annular velocity (Aa), and E/Ea of septal and lateral wall (Table S2) .
Statistical Analysis
The entire analysis process was performed on Stata 12.0 software (StataCorp LLC, College Station, TX). The weighted mean difference (WMD) and corresponding 95% confidence interval (CI) were calculated for the diastolic function measurements between the G1/LVH2 and control groups. The I 2 value was used to assess the heterogeneity among studies. The random effects model was finally adopted, because the statistical heterogeneity was large. To explain the heterogeneity, we carried out subgroup analysis for region (Europe, America, Asia, and Australia), number of involved subjects (more than 50 or not), carrier group female proportion (more than 50% or not) and mean age (younger than 30 years old or not), and univariate meta-regression analysis on the mean age and ejection fraction. In addition, sensitivity analysis and publication bias evaluation were also performed.
Results
Study Characteristics
A total of 1460 studies were found through PubMed (National Center for Biotechnology Information, Bethesda, MD), 521 through Medline (Mundelein, IL), and 1226 through Web of Science (Clarivate Analytics, New York, NY). After removing the obvious irrelevant studies by titles and abstracts, 31 studies with full text were eligible for the assessment. Of these, 14 studies were excluded for their improper grouping or unavailable echocardiographic evaluation. Seventeen eligible studies were included in the systematic review, and 12 of them with Newcastle-Ottawa Scale score 20 of over 6 were included in the meta-analysis ( Figure 1 and Table 1 ).
There were three studies [21] [22] [23] that had been involved in the systematic review but were excluded from the meta-analysis. We excluded two of the studies 21, 23 to avoid publication bias, since they were from the same medical center, written by the same author, and demonstrated similar results with the included studies. 24 The other study 22 provided TDI measurements only in the form of a bar graph rather than mean 6 standard deviation. The result was described as G1/ LVH2 subjects showing increased Aa velocities compared with the control group. There was no difference in Ea velocities between the two groups, and the E/Ea value was not mentioned. (Figure 2 ). In terms of stratified analysis, a lower Ea value was still detectable with smaller heterogeneity in the following subgroups: Europe, female proportion less than 50%, and sample size over 50 ( Table 2 ). The meta-regression analysis could not determine the source of heterogeneity (Supplemental Table S3 ). No statistical significance of publication bias (Table 4) or sensitivity analysis in this research was found. Note: P hetero , P value of heterogeneity.
The boldface highlights the positive results in our research such as the smaller heterogeneity observed in the subgroup analysis.
The asterisks represent nonexistent data in the result of subgroup analysis, since there was only one or none research in some of the subgroup.
Moreover, the G1/LVH2 group showed increased E/Ea compared with the control group (WMD [95% CI] 5 1.363 [0.552, 2.174], P 5 .001, I 2 5 76.0%) (Figure 3 ) when we extracted and analyzed the data from five studies containing septal E/Ea value.
And in the subgroups of Europe, female proportion less than 50%, and sample size over 50, the E/Ea alteration was also detectable with decreased heterogeneity ( Table  2 ). The meta-regression analysis could not explain the large heterogeneity (Supplemental Table S3 ). There was Note: P hetero , P value of heterogeneity.
no positive result of sensitivity analysis or publication bias in this research (Table 4) . The difference between the two groups regarding the Aa value (Supplemental Figure S1 ) of septum had no statistical significance (Table 2) .
TDI Measurements on Lateral Wall Derived Diastolic Function
As for the lateral wall, there was detectable impaired Ea in the G1/LVH2 group (WMD [95% CI] 5 -2.269 [-3.820, -0.719], P 5 .004, I
2 5 87.3%) according to the 10 studies we summarized (Figure 4) . Further stratified analysis demonstrated that the subgroups with fewer female subjects showed remarkably decreased heterogeneity (Table 3 ). The meta-regression analysis could not determine the source of heterogeneity (Supplemental Table S3 ), and no positive result was found from the sensitivity analysis or Begg's test (Table 4) .
In addition, we found increased E/Ea on the lateral wall of the G1/LVH2 group by including seven studies with available lateral E/Ea value (WMD [95% CI] 5 1.339 [0.386, 2.239], P 5 .006, I
2 5 87.1%) (Figure 5) . Subgroup analysis could not determine the source of heterogeneity (Table 3) , and there was no positive result in the sensitivity analysis or Begg's test (Table 4) .
The G1/LVH2 subjects could not be distinguished from the controls by lateral Aa (Supplemental Figure S2 ) except for the subgroup of mean age being younger than 30 and American (Table 3 ).
Discussion
As recommended by the American College of Cardiology, the American Heart Association, the European Society of Cardiology, 34 and the Cardiac Society of Australia and New Zealand, 35 relatives of HCM proband are supposed to carry on clinical screening, including echocardiography and lifelong follow-up, to detect early signs of cardiac event. According to accumulating researches, myocardial dysfunction may be the very early manifestation in the subclinical stage of HCM. Ea and E/Ea is considered to be an ideal parameter in estimating left ventricular filling pressure and diastolic function. 36 However, there is still no uniform conclusion about the usefulness of TDI in detecting subtle alteration of diastolic function. Our meta-analysis, based on systematic reviewing, suggested that TDI-derived diastolic dysfunction exists in the HCM G1/LVH2 groups, and that the diastolic function impairment will be more obvious if we enlarge the sample size.
In our study, diastolic dysfunction of the G1/ LVH2 group was proven. We observed decreased Ea value and increased E/Ea value on both the septum and lateral wall of the G1/LVH2 group. Several experiments have attributed the diastolic dysfunction of G1/ LVH2 subjects to myocyte disarray, interstitial fibrosis, and abnormality in the myocyte itself. 37 Most published studies support that abnormality in the myocyte itself precedes myocyte disarray and interstitial fibrosis, and it plays an important role. First, several HCM genotypes have been proven to lead to myocardial Ca 1 homeostasis dysregulation by increasing the thin filament Ca 1 affinity and Ca 1 binding of troponin complex, making Ca 1 detachment harder during relaxation. 38 Second, myocardial relaxation is known to be an energy-costing process that happens from the end of the systolic phase to the middle of the diastolic phase. 39, 40 Myofilaments showed faster actin sliding velocity and shorter crossbridge cycle, but disproportionate increase in myosin ATPase activity, 41 resulting in accumulation of free Pi and adenosine diphosphate. As is well known, high concentration of Pi and adenosine diphosphatecan prevent the detachment of crossbridge and actin, making myocardial relaxation impaired.
Myocyte disarray was thought to have happened before fibrosis according to a research by Lakdawala in 2011. The G1/LVH2 group lacked interstitial fibrosis, as confirmed by cardiac magnetic resonance examination. However, they still contained echocardiogram abnormalities, which may be caused by myocyte disarray. 42 In the subgroup analysis, we found TDI to be more sensitive in male G1/LVH2 HCM subsets. As for the gender-related phenomenon, we became convinced by the following statement according to several experiments on human beings and animals 43 : Among the HCM gene carriers, the female is usually characterized by lower penetrance and later onset compared with the male, 44 because of the difference in endocrine. Concentrations of estradiol were proven to decrease in overt HCM patients. Estradiol replacement therapy may improve myocardial diastolic function by affecting the mitochondrial ultrastructure, respiration, and biogenesis in several pathways, such as upregulating the expression levels of peroxisome proliferator-activated receptor to ensure oxidative or fatty acid metabolism. Therefore, the higher hormone level of female carriers may be a preventive factor in making the myocardial relaxation impairment delay. [45] [46] [47] [48] [49] [50] [51] Moreover, subgroup analysis showed more Ea and septal E/Ea value impairment in the European subset than in the other regions. There were 155 European, 79 American, 53 Asian, and 7 Australian HCM G1/ LVH2 groups involved in the studies, and Europeans had the heaviest weight in each statistic analysis. Thus, the difference among regions may be the result of sample size.
In addition to the large sample size and gender proportion of these subgroups, we also observed that the alteration of diastolic function measurements was more likely to be detected in younger subsets. The mean age of the two groups was matched in each included study. The healthy older volunteers may have physical degeneration of diastolic function, which makes the difference between the two groups too small to be detected, especially in the very early stage of HCM.
We are aware of some limitations in our study. First, the genotype of HCM carriers involved in the studies was not completely available. Second, we only searched for studies written in English. Third, because of the limitation of sample size, significant heterogeneity exists in some of the comparisons and cannot be completely explained by subgroup analysis, sensitivity analysis, and meta-regression.
In conclusion, our systematic review and metaanalysis demonstrated that diastolic dysfunction derived by TDI, as an early manifestation, can be observed in HCM G1/LVH2 subjects, especially in the subgroups with larger sample size, fewer female subjects, younger mean age, and more Europeans. Therefore, we recommend it as a routine, noninvasive method in the followup of HCM G1/LVH2 subjects.
